Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.09, Zacks reports.
Achieve Life Sciences Price Performance
ACHV opened at $6.71 on Thursday. The stock has a market cap of $689.96 million, a P/E ratio of -4.33 and a beta of 2.42. Achieve Life Sciences has a 12 month low of $2.62 and a 12 month high of $8.64. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.87. The company has a fifty day simple moving average of $7.23 and a 200 day simple moving average of $5.70.
Insiders Place Their Bets
In other Achieve Life Sciences news, Director Richard Stewart sold 20,626 shares of Achieve Life Sciences stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total transaction of $175,114.74. Following the transaction, the director directly owned 208,249 shares in the company, valued at approximately $1,768,034.01. The trade was a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.80% of the company’s stock.
Analyst Ratings Changes
Several equities analysts have weighed in on the company. Raymond James Financial reissued a “strong-buy” rating and issued a $18.00 target price on shares of Achieve Life Sciences in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Wednesday, August 19th. Stifel Nicolaus set a $18.00 price target on shares of Achieve Life Sciences and gave the company a “buy” rating in a research report on Tuesday, September 29th. HC Wainwright reissued a “buy” rating on shares of Achieve Life Sciences in a research note on Friday, October 23rd. Finally, Wall Street Zen lowered shares of Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.50.
Read Our Latest Analysis on ACHV
About Achieve Life Sciences
Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead candidate, cytisinicline, is an oral medication being studied to help people stop smoking and quit using nicotine-containing products, including e-cigarettes. Cytisinicline is a plant-derived compound that acts on nicotinic receptors in the brain. Achieve is evaluating it in clinical trials; it is not an approved commercial product. The company’s development efforts have focused primarily on the U.S. market.
Read More
- Five stocks we like better than Achieve Life Sciences
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
